MediSpectra claims US market first for LUMA cervical imaging system
This article was originally published in Clinica
MediSpectra has finally received US market approval for its LUMA cervical imaging system, which it claims is the first optical imaging device approved to help examine women with abnormal PAP smears. The company suffered a blow in May last year when an FDA advisory panel voted against the device's clearance, over concerns that clinical data failed to meet specified endpoints, and that detection rates were no better than biopsy.
You may also be interested in...
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.